IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

Stella Lee +2 more

Learning objectives

Review the inflammatory endotypes observed in CRSwNP, zooming in on the key role of type 2 cytokines, IL-4, IL-13, and IL-5
Understand the underappreciated burden on health-related quality of life, and the importance of bringing patients into the decision-making process
Define the concepts of statistical significance and clinical importance and the advantages of considering clinically important symptom improvements in patients with CRSwNP
Review evidence of improvements in olfaction with surgery and biologics from real-world effectiveness studies and randomized controlled trials and safety of biologics in patients with CRSwNP

About these experts

Rhinology

Stella Lee

Chief of Rhinology at Brigham and Women’s Hospital | Harvard Medical School, Boston, United States

Rhinology

MD, PhD

Peter Hellings

Professor and Clinic Head of the Department of Otorhinolaryngology | University Hospitals of Leuven, Belgium

Rhinology

MD, PhD

Wytske Fokkens

Professor in the Department of Otorhinolaryngology | Academic Medical Center, Amsterdam, Netherlands; Director | European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA)

This website is intended for healthcare professionals practicing in Romania.

The Summary Product Characteristics of Dupilumab is available here.

Dupilumab is dispensed on medical prescription type PR.

For the request of medical information, the reporting of adverse reactions and / or quality complaints, please call the call center service 24/7, phone (+40) 021 317 31 36, or contact us by email at the following addresses: ro.medical_info@sanofi.com - Medical Department, quality.ro@sanofi.com - Quality Department, pv.ro@sanofi.com - Pharmacovigilance Department.

You may also report adverse reactions to Sanofi medicinal products to the National Agency for Medicines and Medical Devices from Romania (NAMMDR); for details on reporting side effects, visit the NAMMDR website.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: RomaniaChange country/region